Skip to content

Study on the Effect of APOC3 on Liver Function in Patients with Non-alcoholic Fatty liver Disease after Liver Cancer resection

Study on the Effect of APOC3 on Liver Function in Patients with Non-alcoholic Fatty liver Disease after Liver Cancer resection

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116312
Enrollment
Unknown
Registered
2026-01-08
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

Normal liver function group :None
impaired liver function group:None

Sponsors

Affiliated Hospital of Guangdong Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for the control group (normal liver function group) : 1. Pathological diagnosis of hepatocellular carcinoma 2. Normal liver function both before and after the operation (for liver dysfunction, refer to the diagnostic criteria of this study) 3. No radiotherapy, chemotherapy, targeted therapy or other adjuvant treatments were received before the operation. 4. All were the first surgical treatments. 5.No other malignant tumors were combined; 6. Patients and their families were informed of this study and voluntarily joined it. Inclusion criteria for the case group (liver dysfunction group) : 1 The pathological diagnosis was hepatocellular carcinoma. 2. The liver function was normal before the operation. 3. The liver function was impaired after the operation. 4. No radiotherapy, chemotherapy, targeted therapy or other adjuvant therapy was received before the operation. 5. All were undergoing surgical treatment for the first time. 6. No other malignant tumors were combined. 7. Patients and their families were informed of this study and voluntarily participated in it

Exclusion criteria

Exclusion criteria: 1. Previously received TACE, chemotherapy, radiotherapy or targeted immunotherapy; 2. Total time of multiple hepatic portal occlusion during the operation > 60 minutes; 3. There are serious heart and lung diseases; 4. There is distant metastasis.

Design outcomes

Primary

MeasureTime frame
The changes in APOC3 content before and after hepatic portal occlusion;

Secondary

MeasureTime frame
One day before the operation, APOC3;One day after the operation, APOC3;One day before the operation, AST;One day after the operation, AST;One day before the operation, AST;One day after the operation, ALT;One day before the operation, LDH;One day after the operation,LDH;Total bilirubin one day before the operation;Total bilirubin one day after the operation;Coagulation function one day before the operation;Coagulation function one day after the operation;

Countries

China

Contacts

Public ContactMo Jian

Affiliated Hospital of Guangdong Medical University

1127350246@qq.com+86 137 0273 1555

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026